Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development

European Journal of Cancer

Volumn 40, Issue 6, 2004, Pages 837-844

  Peterson, J K ^a   Houghton, P J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Molecular targets; Paediatric cancer; Pharmacodynamics; Pharmacokinetics; Xenografts

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 6 HYDROXYMETHYLACYLFULVENE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; BISNAFIDE MESYLATE; CARZELESIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; FLUOROURACIL; IMATINIB; IRINOTECAN; MELPHALAN; SEMUSTINE; SULOFENUR; TOPOTECAN; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; CANCER; CANCER MODEL; CHILDHOOD CANCER; CLINICAL TRIAL; COLON ADENOCARCINOMA; DRUG ACTIVITY; DRUG PROTEIN BINDING; DRUG SENSITIVITY; HUMAN; MAXIMUM TOLERATED DOSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHABDOMYOSARCOMA; RODENT; SOLID TUMOR; TRANSGENIC MOUSE; TREATMENT FAILURE; TUMOR XENOGRAFT;

EID: 1942422737     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.01.003     Document Type: Article

References (31)

1. Johnson J.I., Decker S., Zaharevitz D.et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer. 84:2001;1424-1431.
2. Heterotransplantation of human adenocarcinomas of the colon and rectum to the mouse mutant Nude. A study of nine consecutive transplantations. Acta Pathol. Microbiol. Scand. [A]. 79:1971;159-169.
3. Rygaard J., Povlsen C.O. Heterotransplantation of a human malignant tumour to "Nude" mice. Acta Pathol. Microbiol. Scand. 77:1969;758-760.
4. Lock R.B., Liem N., Farnsworth M.L.et al. The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. Blood. 99:2002;4100-4108.
5. Houghton J.A., Cook R.L., Lutz P.J., Houghton P.J. Childhood rhabdomyosarcoma xenografts. responses to DNA-interacting agents and agents used in current clinical therapy Eur. J. Cancer Clin. Oncol. 20:1984;955-960.
6. Houghton P.J., Horton J.K., Houghton J.A. Drug sensitivity and resistance in the xenograft model. Maurer H.M., Ruyman F.B., Pochedly C. Rhabdomyosarcoma and Related Tumors in Children and Adolescents. 1991;187-202 CRC Press, Boca Raton.
7. Houghton J.A., Cook R.L., Lutz P.J., Houghton P.J. Melphalan. a potential new agent in the treatment of childhood rhabdomyosarcoma Cancer Treat. Rep. 69:1985;91-96.
8. Horowitz M.E., Etcubanas E., Christensen M.L.et al. Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma. a model for anticancer drug development J. Clin. Oncol. 6:1988;308-314.
9. Houghton P.J., Cheshire P.J., Hallman III J.C. Evaluation of a novel bis-naphthalimide anticancer agent, DMP 840, against human xenografts derived from adult, juvenile, and pediatric cancers. Cancer Chemother. Pharmacol. 33:1994;265-272.
10. Houghton P.J., Cheshire P.J., Hallman 2nd J.D., Houghton J.A. Therapeutic efficacy of the cyclopropylpyrroloindole, carzelesin, against xenografts derived from adult and childhood solid tumors. Cancer Chemother. Pharmacol. 36:1995;45-52.
11. Houghton P.J., Houghton J.A., Myers L., Cheshire P., Howbert J.J., Grindey G.B. Evaluation of N-(5-indanylsulfonyl)-N′-(4-chlorophenyl)-urea against xenografts of pediatric rhabdomyosarcoma. Cancer Chemother. Pharmacol. 25:1989;84-88.
12. Pappo A.S., Lyden E., Breneman J.et al. Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma. an intergroup rhabdomyosarcoma study J. Clin. Oncol. 19:2001;213-219.
13. Furman W.L., Stewart C.F., Poquette C.A.et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J. Clin. Oncol. 17:1999;1815-1824.
14. Cosetti M., Wexler L.H., Calleja E.et al. Irinotecan for pediatric solid tumors. the Memorial Sloan-Kettering experience J. Pediatr. Hematol. Oncol. 24:2002;101-105.
15. Santana V.M., Zamboni W.C., Kirstein M.N.et al. A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. Clin. Cancer Res. 9:2003;633-640.
16. Zamboni W.C., Stewart C.F., Thompson J.et al. Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J. Natl. Cancer Inst. 90:1998;505-511.
17. Santana V.M., Zamboni W.C., Gajjar A.et al. Pharmacokinetically-guided use of topotecan (TPT), given (daily×5)×2, in children with relapsed solid tumors. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 16:1997;1839A.
18. Leggas M., Stewart C.F., Woo M.H.et al. Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts. Clin. Cancer Res. 8:2002;3000-3007.
19. Eckhardt S.G., Baker S.D., Britten C.D.et al. Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies. J. Clin. Oncol. 18:2000;4086-4097.
20. Ritschel W.A., Vachharajani N.N., Johnson R.D., Hussain A.S. The allometric approach for interspecies scaling of pharmacokinetic parameters. Comp. Biochem. Physiol. C. 103:1992;249-253.
21. Nomura T., Sakurai Y., Inaba M. The Nude Mouse and Anticancer Drug Evaluation. 1996;Japanese Journal of Cancer and Chemotherapy Publishers Inc, Tokyo.
22. Lave T., Portmann R., Schenker G.et al. Interspecies pharmacokinetic comparisons and allometric scaling of napsagatran, a low molecular weight thrombin inhibitor. J. Pharm. Pharmacol. 51:1999;85-91.
23. Luttringer O., Theil F.P., Poulin P., Schmitt-Hoffmann A.H., Guentert T.W., Lave T. Physiologically based pharmacokinetic (PBPK) modeling of disposition of epiroprim in humans. J. Pharm. Sci. 92:2003;1990-2007.
24. Poulin P., Theil F.P. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J. Pharm. Sci. 91:2002;129-156.
25. Moody S.E., Sarkisian C.J., Hahn K.T.et al. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell. 2:2002;451-461.
26. Sebolt-Leopold J.S., Dudley D.T., Herrera R.et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat. Med. 5:1999;810-816.
27. Houghton P.J., Adamson P.C., Blaney S.et al. Testing of new agents in childhood cancer preclinical models. meeting summary Clin. Cancer Res. 8:2002;3646-3657.
28. Weiss W.A., Aldape K., Mohapatra G., Feuerstein B.G., Bishop J.M. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J. 16:1997;2985-2995.
29. Sharp R., Recio J.A., Jhappan C.et al. Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. Nat. Med. 8:2002;1276-1280.
30. Wetmore C., Eberhart D.E., Curran T. Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched. Cancer Res. 61:2001;513-516.
31. Mordenti J. Dosage regimen design for pharmaceutical studies conducted in animals. J. Pharm. Sci. 75:1986;852-857.